United Therapeutics Corp
Change company Symbol lookup
Select an option...
UTHR United Therapeutics Corp
KEX Kirby Corp
DDOG Datadog Inc
CLX Clorox Co
ATTO Atento SA
TOWN TowneBank
CHWY Chewy Inc
O Realty Income Corp
HOOK HOOKIPA Pharma Inc
AI C3.ai Inc
Go

Health Care : Biotechnology | Mid Cap Value
Company profile

United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Tyvaso (treprostinil) Inhalation Solution (Tyvaso), which includes the Tyvaso Inhalation System; Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso and Tyvaso DPI are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKinds Afrezza (insulin human) Inhalation Powder product.

Postmarket

Last Trade
Delayed
$209.74
-3.74 (-1.75%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$213.48
Day's Change
3.74 (1.78%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
214.54
Day's Low
207.00
Volume
(Above Average)
Volume:
483,995

10-day average volume:
428,588
483,995

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.